Michael Mingzhao Xing, M.D., Ph.D., is tenured Professor of Medicine, Oncology, Pathology, and Cellular & Molecular Medicine, Director of the Johns Hopkins Thyroid Tumor Center, and Chief of the Laboratory for Cellular and Molecular Thyroid Research at the Johns Hopkins University School of Medicine.
He previously received medical training at the Second Military Medical University in Shanghai, China and Ph.D. training at Case Western Reserve University in Cleveland, Ohio, USA. He received medical residency training at Greater Baltimore Medical Center and clinical endocrinology fellowship training at Johns Hopkins Hospital in Baltimore, Maryland, USA. American board-certified dually in Internal Medicine and Endocrinology & Metabolism, for the last nearly two decades, Dr. Xing has been working at Johns Hopkins Hospital as an endocrine subspecialty consultant and teaching attending while directing a thyroid research laboratory as a physician scientist there.
His main clinical and research interests are in thyroid diseases, particularly thyroid tumor. Supported by the American Cancer Society and continuous NIH R0-1 grants, his laboratory has been studying molecular, genetic, and epigenetic mechanisms of thyroid cancer and their clinical translation.
He has >170 publications in various prestigious journals, such as JCEM, Clinical Cancer Research, Cancer Research, Journal of Clinical Investigation, Journal of National Cancer Institute, Journal of Clinical Oncology, Nature Communications, JAMA Oncology, Lancet, JAMA, Nature Reviews Cancer, and Endocrine Reviews.
He holds/co-holds eight USA patents on such thyroid research contributions as initial discovery and clinical characterization of the BRAF V600E and TERT promoter mutations in thyroid cancer and initial demonstration of targeting BRAF/MEK to restore thyroid gene expression and radioiodine uptake for radioiodine treatment of thyroid cancer. His work has had a profound impact on today's molecular-based management of thyroid tumor and is consistently among world's top 1% citations in the thyroid field (received nearly 17,000 citations). He received the 2006 Maryland Innovator Award, the 2013 British Endocrine Society's Endocrine-Related Cancer Research Award, the 2014 Chinese Endocrine Society's Zhu Xianyi Award, the 2016 American Thyroid Association's Paul Starr Award, and the Johns Hopkins' 2017 Paul W Ladenson Thyroid Award. He has been consistently recognized among the "World's Top 10 Thyroid Cancer Scholar Experts" by Expertscape and "America's Top Doctors" by US News & World Reports and other professional recognition entities. He is an elected member of the Association of American Physicians.
He has been a standing or frequent ad hoc member on grant committees of NIH and other institutions in the world and served several leadership roles at the American Thyroid Association, including the Research Committee Chair, Associate Editor of the journal Thyroid, and Scientific Chair of the 2016-2017 ATA Annual Meeting Program Committee.